Molecular Partners (MOLN)
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology...
- Open
- 4.670
- High
- 4.670
- Low
- 4.500
- Prev. Close
- 4.652
- Volume
- 1.55K
- Turnover
- 7.21K
- Avg Price
- 4.640
- Bid/Ask Ratio
- --
- Amplitude
- 3.65%
- 52wk High
- 5.360
- Volume Ratio
- 2.41
- Turnover Ratio
- 0.01%
Molecular Partners Analyst Rating
View moreForecast & Rating
Aug 26, 2026Price forecast
$10.78139.64%
Forecast & RatingStrong buy
5analysts
- Strong buy80.00%
- Buy0.00%
- Hold20.00%
- Sell0.00%
- Strong sell0.00%
News
- Tip Ranks · Aug 25 at 03:15 PM
Molecular Partners: Pipeline Momentum and Early Safety Data Support Unchanged $12 Price Target and Buy Rating
- businessinsider · Aug 25 at 07:00 AM
Molecular Partners GAAP EPS of -CHF0.70
- Quartr · Aug 25 at 02:21 AM
MOLN: MP0712 advances in SCLC trials, CD70 program announced, and cash runway extends into late 2027
- Quartr · Aug 25 at 12:12 AM
MOLN: Cash of CHF 68M supports advancing DARPin oncology pipeline, with key data expected in 2026
- PUBT · Aug 25 at 12:00 AM
Molecular Partners H1 FY26 net loss narrows to CHF 26.7 million; operating loss improves to CHF 27 million
- StockTitan · Aug 24 at 04:00 PM
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study | MOLN Stock News
